Obermatt
See Similar Stocks →

Fennec Pharmaceuticals

NAQ:FENC · CA31447P1009
BiotechnologySmall

360

62
Medium confidence — indicative
Profit price—
Cash yield—
Price/Sales80
EV / Gross Profit30
Price/Book28
Return on Capital75
Return on Equity57
EBIT Margin62
Gross Profitability94

Cash truth not applicable for financial companies.

Sales growth70
Profit growth93
Reinvestment81
Price momentum29
Debt load36
Debt serviceability94
Liquidity69
Analyst ratings56
Opinion Changes91
Price Target Upside25
Market mood29
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Fennec Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 1/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1996
Employees49
Websitefennecpharma.com
ISINCA31447P1009
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Ear Nose & Throat (ENT)OncologyBiotechnologyHealth CarePharmaceutical

Description

Fennec Pharmaceuticals Inc. (Fennec) operates as commercial stage biopharmaceutical company. The company operates as a commercial-stage specialty pharmaceutical company dedicated to preventing cisplatin-induced ototoxicity (CIO), a serious and often…

Analysis

Middle-of-the-road

Fennec Pharmaceuticals Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is stretched. The company scores 20/20 on our value-creation score: strong value creator.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
86
2026

All-time high

96

Mar 2026

All-time low

86

Jun 2026

Average rank

91

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
80
—
—
—
Price/Earnings
3
—
—
—
Price/Book
28
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
42
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Fennec Pharmaceuticals with its peers
Seres Therapeutics
NSQ:MCRB
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immuneering
NMQ:IMRX
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
TriSalus Life Sciences
NMQ:TLSI
62
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Bicara Therapeutics
NMQ:BCAX
43
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sarepta Therapeutics
NSQ:SRPT
69
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Abeona Therapeutics
NAQ:ABEO
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →